637 related articles for article (PubMed ID: 31852716)
41. Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.
Weiskopf K; Anderson KL; Ito D; Schnorr PJ; Tomiyasu H; Ring AM; Bloink K; Efe J; Rue S; Lowery D; Barkal A; Prohaska S; McKenna KM; Cornax I; O'Brien TD; O'Sullivan MG; Weissman IL; Modiano JF
Cancer Immunol Res; 2016 Dec; 4(12):1072-1087. PubMed ID: 27856424
[TBL] [Abstract][Full Text] [Related]
42. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
43. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
44. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection.
Cham LB; Torrez Dulgeroff LB; Tal MC; Adomati T; Li F; Bhat H; Huang A; Lang PA; Moreno ME; Rivera JM; Galkina SA; Kosikova G; Stoddart CA; McCune JM; Myers LM; Weissman IL; Lang KS; Hasenkrug KJ
Cell Rep; 2020 Apr; 31(2):107494. PubMed ID: 32294445
[TBL] [Abstract][Full Text] [Related]
46. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
47. Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas.
Jain S; Van Scoyk A; Morgan EA; Matthews A; Stevenson K; Newton G; Powers F; Autio A; Louissaint A; Pontini G; Aster JC; Luscinskas FW; Weinstock DM
Blood; 2019 Oct; 134(17):1430-1440. PubMed ID: 31383641
[TBL] [Abstract][Full Text] [Related]
48. The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions.
Osorio JC; Smith P; Knorr DA; Ravetch JV
Cancer Cell; 2023 Dec; 41(12):2051-2065.e6. PubMed ID: 37977147
[TBL] [Abstract][Full Text] [Related]
49. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
[TBL] [Abstract][Full Text] [Related]
50. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.
Tsao LC; Crosby EJ; Trotter TN; Agarwal P; Hwang BJ; Acharya C; Shuptrine CW; Wang T; Wei J; Yang X; Lei G; Liu CX; Rabiola CA; Chodosh LA; Muller WJ; Lyerly HK; Hartman ZC
JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31689243
[TBL] [Abstract][Full Text] [Related]
51. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
52. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
53. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
54. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
[TBL] [Abstract][Full Text] [Related]
55. CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.
Tang Z; Zhong MC; Qian J; Galindo CC; Davidson D; Li J; Zhao Y; Hui E; Veillette A
Nat Immunol; 2023 Dec; 24(12):2032-2041. PubMed ID: 37945822
[TBL] [Abstract][Full Text] [Related]
56. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody.
Seckinger A; Buatois V; Moine V; Daubeuf B; Richard F; Chatel L; Viandier A; Bosson N; Rousset E; Masternak K; Salgado-Pires S; Batista C; Mougin C; Juan-Bégeot F; Poitevin Y; Hose D
Front Immunol; 2024; 15():1378813. PubMed ID: 38720892
[TBL] [Abstract][Full Text] [Related]
57. Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
Zhang X; Wang Y; Fan J; Chen W; Luan J; Mei X; Wang S; Li Y; Ye L; Li S; Tian W; Yin K; Ju D
J Immunother Cancer; 2019 Dec; 7(1):346. PubMed ID: 31829270
[TBL] [Abstract][Full Text] [Related]
58. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.
Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H
Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925
[TBL] [Abstract][Full Text] [Related]
59. AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and Activating Fc Receptors.
Yang J; Deresa I; Ho WH; Long H; Maslyar D; Rosenthal A; Liang SC; Pincetic A
J Immunol; 2023 Jan; 210(2):204-215. PubMed ID: 36480261
[TBL] [Abstract][Full Text] [Related]
60. Is CD47 an innate immune checkpoint for tumor evasion?
Liu X; Kwon H; Li Z; Fu YX
J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
